patent.fyi
Applications  /  US 2026/0355223
United States Patent Application Publication

US 2026/0355223 A1

Published
Nov 12, 2026
Filed
May 12, 2026
Earliest date on the face
May 12, 2025
Classification
A61K 31/675
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Incentives tied to urine results

What ifWhat if the treatment uses incentives tied to cocaine-negative urine results?
Claim language“psilocybin or a pharmaceutical composition thereof”

A clinic tests scheduled urine samples for benzoylecgonine, a cocaine metabolite. Staff issue a voucher after each negative result and increase its value after consecutive negative results.

1.1Coping skills for cocaine cues

What ifWhat if the treatment uses structured coping skills sessions?
Claim language“psilocybin or a pharmaceutical composition thereof”

A therapist and patient review recent cocaine use episodes to identify triggers, thoughts, and responses. The patient rehearses specific responses to high-risk situations and records which responses they use between sessions.

1.1Scheduled activities that support abstinence

What ifWhat if the treatment uses a weekly schedule of rewarding activities that support abstinence?
Claim language“psilocybin or a pharmaceutical composition thereof”

A counselor helps the patient identify when and where cocaine use occurs. The patient schedules accessible social, recreational, or work activities during those periods and reviews participation with the counselor each week.

1.1Structured sessions on readiness

What ifWhat if the treatment uses structured interviews to build readiness to reduce cocaine use?
Claim language“psilocybin or a pharmaceutical composition thereof”

A counselor uses open questions and reflective listening to elicit the patient's reasons for changing cocaine use. The patient selects a goal and reviews progress toward that goal at the next session.

1.1Peer support for recovery

What ifWhat if the treatment uses facilitated peer support meetings?
Claim language“psilocybin or a pharmaceutical composition thereof”

A facilitator leads recurring meetings in which participants discuss recent triggers and identify concrete responses. Each participant sets a recovery goal for the next interval and reviews progress at the following meeting.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Administration in a rodent research facility

A preclinical research facility pairs psilocybin administration with an operant chamber in a rodent model of cocaine seeking. The chamber contains an active lever that triggers a light cue previously paired with cocaine delivery and an inactive lever that triggers no cue. After administration, a chamber controller timestamps presses on both levers during a fixed observation period and stores the counts by animal and session.

Component substitution

Psilocin as the administered compound

A clinical research protocol substitutes psilocin, the active metabolite of psilocybin, as the administered compound. A pharmacy record links each dispensed unit to its batch identifier and measured psilocin content. Timed blood samples are analyzed by liquid chromatography with tandem mass spectrometry to characterize exposure after administration.

Parameter or scale variation

Follow-up at three fixed intervals

A follow-up schedule places three assessments at 7, 28, and 84 days after a psilocybin administration session. Each assessment uses the same structured interview to record the number of days with cocaine use during the preceding seven days. A study database calculates the target dates from the administration timestamp and stores the actual assessment dates alongside the results.

Combination with existing systems

Administration linked to laboratory testing

An electronic study record connects the psilocybin administration record to a laboratory information system that processes urine specimens. Each specimen receives a barcode linked to the participant identifier and scheduled visit. The laboratory system returns the measured concentration of benzoylecgonine, a cocaine metabolite, together with the specimen collection time for review alongside reported cocaine use.

Vital sign monitoring during administration

A bedside monitor combines an automated blood pressure cuff with a pulse oximeter during a supervised psilocybin administration session. The monitor records intermittent blood pressure readings and a continuous pulse and oxygen saturation stream on a shared time base. A session record aligns the measurements with the administration timestamp and flags readings that cross clinician-configured thresholds for staff review.

Automated or data-driven variant

Automated capture of daily cocaine craving

A mobile application prompts the participant to record cocaine craving on a scale from 0 to 10 during the week before psilocybin administration and the four weeks after it. The application timestamps each response and records missed prompts separately. A study dashboard displays weekly average scores and response counts so reviewers can see how many observations contribute to each average.

Specific version of a part

Hard shell oral capsule

A two-piece cellulose capsule contains a measured mass of psilocybin blended with a pharmaceutical filler. The patient swallows the capsule under observation during a monitored investigational session.

Compressed immediate release tablet

A compressed tablet contains psilocybin, a binder, and a disintegrant. The disintegrant promotes breakup after swallowing, and a dissolution test measures release from the tablet.

Measured oral liquid dose

An oral solution contains psilocybin at a specified concentration. Staff measure the volume corresponding to the protocol dose with a graduated oral syringe and record the volume administered.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2021/0015738 A1
Published
Jan 21, 2021
Filed
Jul 14, 2020
Class
A61K 9/006
Document BUS 2023/0089848 A1
Published
Mar 23, 2023
Filed
Sep 19, 2022
Class
A61K 31/675
Claim 1
Document A
Document B
1.1the step of administering to the mammal a therapeutically effective amount of psilocybin or a pharmaceutical composition thereof.
Also provided is a method of treating in a subject a disease or disorder ameliorated by a psychedelic compound, that includes orally administering to a subject an oral dissolvable film that includes a therapeutically effective amount of the psychedelic compound.
A · US 2021/0015738 A1 · abstract
In some embodiments, administering an alkaloid composition to treat, prevent, or ameliorate a disease, as described herein, can comprise using a macro-dosing regimen. A macro-dosing regimen may comprise the administration of an alkaloid composition comprising a macro-dose once.
B · US 2023/0089848 A1 · ¶ 33

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention also provides for a method of improving creativity, boosting physical energy level, attaining emotional balance, improving the mood, and/or increasing performance on problem-solving tasks.
A · US 2021/0015738 A1 · ¶ 6
The present invention also provides for a method of orally administering to a subject an oral dissolvable film described herein, wherein the oral dissolvable film includes a low dose or microdose of the psychedelic compound.
A · US 2021/0015738 A1 · ¶ 7
Although some research has into depression and similar disorders, needs exist for the identification of psilocybin for other therapeutic and nutraceutical uses.
B · US 2023/0089848 A1 · ¶ 3
As such, by providing psilocybin and other compounds that activate the 5-HT2A receptor, alone or in combination with each other and/or other compounds, as pharmaceutical agents and/or dietary supplements, therapeutic and nutraceutical benefits can be realized, either individually, collectively, or in conjunction with other pharmaceutical agents and/or dietary supplements.
B · US 2023/0089848 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355223 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355223/, SHA-256 cfacf561a1fef4dc7af0c7c9cec4f3744477470a36a446ed9e4110408386b1db
First published
Permanent addresshttps://patent.fyi/US20260355223/
Content fingerprint (SHA-256)cfacf561a1fef4dc7af0c7c9cec4f3744477470a36a446ed9e4110408386b1db
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi